SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives $12.00 Average Target Price from Analysts

SAB Biotherapeutics, Inc. (NASDAQ:SABS) has received an average recommendation of “Moderate Buy” from the eleven research firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $12.00.

Several analysts have weighed in on the company. Rodman & Renshaw reissued a “buy” rating and set a $13.00 price objective on shares of SAB Biotherapeutics in a report on Monday, May 11th. Zacks Research upgraded shares of SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 11th. Jefferies Financial Group started coverage on shares of SAB Biotherapeutics in a research note on Wednesday, May 20th. They set a “buy” rating and a $11.00 price target for the company. Barclays initiated coverage on shares of SAB Biotherapeutics in a report on Wednesday, June 24th. They issued an “overweight” rating and a $13.00 price objective on the stock. Finally, Chardan Capital raised their price objective on shares of SAB Biotherapeutics from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Wednesday, June 17th.

SAB Biotherapeutics Price Performance

Shares of SABS opened at $3.54 on Friday. The business’s fifty day moving average price is $3.71 and its two-hundred day moving average price is $3.85. The firm has a market capitalization of $270.67 million, a price-to-earnings ratio of -1.68 and a beta of 0.52. SAB Biotherapeutics has a 52 week low of $1.85 and a 52 week high of $6.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.45 and a current ratio of 11.45.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.15). On average, analysts predict that SAB Biotherapeutics will post -1.19 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. PNC Financial Services Group Inc. acquired a new stake in shares of SAB Biotherapeutics during the first quarter worth $29,000. ADAR1 Capital Management LLC acquired a new position in shares of SAB Biotherapeutics during the 3rd quarter worth about $30,000. Dimensional Fund Advisors LP acquired a new position in shares of SAB Biotherapeutics during the 3rd quarter worth about $32,000. State of Wyoming bought a new stake in shares of SAB Biotherapeutics in the 4th quarter valued at about $34,000. Finally, Virtu Financial LLC bought a new stake in shares of SAB Biotherapeutics in the 3rd quarter valued at about $40,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.